{"id":122121,"date":"2017-06-14T17:00:07","date_gmt":"2017-06-14T17:00:07","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=122121"},"modified":"2017-06-14T17:00:07","modified_gmt":"2017-06-14T17:00:07","slug":"global-injectable-drug-delivery-market-will-be-worth-usd-7897-billion-by-2024-new-market-report-by-data-bridge-market-research","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-injectable-drug-delivery-market-will-be-worth-usd-7897-billion-by-2024-new-market-report-by-data-bridge-market-research_122121.html","title":{"rendered":"Global Injectable Drug Delivery Market will be worth USD 789.7 billion by 2024 &#8211; New market report by Data Bridge Market Research"},"content":{"rendered":"<div style=\" width:250px; padding:8px 10px 10px 10px; float:right;\"><a href=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2017\/06\/1479920915.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"image\" src=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2017\/06\/1479920915.png\" alt=\"\" width=\"225\" height=\"65\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\" style=\" font-weight:bold; font-style:italic;\">\n<div>&#8220;Global Injectable Drug Delivery Market is expected to grow at 11.5% in the forecast period 2017 to 2024&#8221;<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration  (Skin, Circulatory, Organs, Central Nervous System), End User, Geography  \u2013 Industry Trends and Forecast to 2024 <\/div>\n<p style=\"text-align: justify;\">Global injectable drug delivery is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.<\/p>\n<p style=\"text-align: justify;\">Global injectable drug delivery market is segmented based on product type, applications, mode of administration, usage pattern, end-user and geography.<\/p>\n<p style=\"text-align: justify;\">On the basis of type the market is further segmented into Devices and formulation. Devices are further segmented into Conventional Injection, Self-Injection whereas Formulations are further segmented into Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations.<\/p>\n<p style=\"text-align: justify;\"><strong>For Sample Report: <\/strong><a rel=\"nofollow\" href=\"http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/\">Global Injectable Drug Delivery Market &ndash; Industry Trends and Forecast to 2024<\/a><\/p>\n<p style=\"text-align: justify;\">Based on Application the market is further segmented into Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology.<\/p>\n<p style=\"text-align: justify;\">Based on Usage Pattern the market is further segmented into Curative Care, Immunizations.<\/p>\n<p style=\"text-align: justify;\">Based on Mode of Administration the market is further segmented into Skin, Circulatory, Organs, Central Nervous System.<\/p>\n<p style=\"text-align: justify;\">Based on End User the market is further segmented into Hospitals &amp; Clinics, Home Care Settings, Research Laboratories,&nbsp; Pharma &amp; Biotech Companies<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To read more about the scope and findings of this report visit:<\/strong> <a rel=\"nofollow\" href=\"http:\/\/databridgemarketresearch.com\/global-injectable-drug-delivery-market-is-growing-at-a-significant-rate-in-the-forecast-period-2017-2024\/\">Global Injectable Drug Delivery Market Is Growing At A Significant Rate In The Forecast Period 2017-2024<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Based on geography the Injectable Drug Delivery Market is segmented into North &amp; South America, Europe, Asia-Pacific and, Middle East &amp; Africa. North America is expected to dominate the market for Injectable Drug Delivery in 2016 and expected to be growing with highest CAGR in the forecast period 2017 &#8211; 2024.The report of this market shares countries such as U.S., Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among other companies.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/\" target=\"_blank\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"http:\/\/www.abnewswire.com\/uploads\/56c78dbcc6f3cb01d12cb4797658a4dc.jpg\" alt=\"\" \/><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>KEY PLAYERS OPERATING IN GLOBAL INJECTABLE DRUG DELIVERY MARKET:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Baxter International, Inc.<\/li>\n<li>Becton Dickinson and Company<\/li>\n<li>Gerresheimer AG<\/li>\n<li>Pfizer, Inc.<\/li>\n<li>Schott AG<\/li>\n<li>Alkermes Plc.,<\/li>\n<li>Eli Lilly and Company<\/li>\n<li>Sandoz<\/li>\n<li>Terumo Corporation<\/li>\n<li>Teva Pharmaceuticals Industries Ltd.<\/li>\n<li>Bespak<\/li>\n<li>Antares Pharma<\/li>\n<li>Elcam Medical,<\/li>\n<li>Haselmeier, Mylan N.V.<\/li>\n<li>Novo Nordisk<\/li>\n<li>Owen Mumford Ltd<\/li>\n<li>Sanofi<\/li>\n<li>West Pharmaceutical Services, Inc<\/li>\n<li>Ypsomed Holding AG<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Enquire about the report:<\/strong> <a rel=\"nofollow\" href=\"http:\/\/databridgemarketresearch.com\/inquire-before-buying\/?chalet=Global%20Injectable%20Drug%20Delivery%20Market\">Global Injectable Drug Delivery Market &ndash; Industry Trends and Forecast to 2024<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. INTRODUCTION<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;1.2. MARKET SEGMENTATION &amp; COVERAGE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1.2.1. CURRENCY AND PRICING<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1.2.2. LIMITATION<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1.2.3. STAKEHOLDERS<\/p>\n<p style=\"text-align: justify;\">2. RESEARCH METHODOLOGY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;2.1. KEY TAKEAWAYS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2.2.1. MARKET CRACKDOWN APPROACH<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2.2.3. DATA TRIANGULATION<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2.2.6. PORTER&rsquo;S FIVE FORCES MATRIX<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;2.4. ASSUMPTIONS<\/p>\n<p style=\"text-align: justify;\">3. MARKET LANDSCAPE SUMMARY<\/p>\n<p style=\"text-align: justify;\">4. PREMIUM INSIGHTS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;4.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;4.3. MARKET OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 4.3.1. DRIVERS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 4.3.2. RESTRAINTS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 4.3.3.&nbsp;OPPORTUNITIES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 4.3.4. THREATS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.4.1. PRODUCT RECALLS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.4.2. REGULATORY HURDLES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.4.3. STABILITY OF PRODUCTS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.4.4. STERILITY OF INJECTIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES<\/p>\n<p style=\"text-align: justify;\">5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;5.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;5.2. INJECTABLE DRUG DELIVERY DEVICES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;5.3. INJECTABLE DRUG DELIVERY FORMULATIONS<\/p>\n<p style=\"text-align: justify;\">6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;6.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;6.2. CONVENTIONAL INJECTION DEVICES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.2.1. BY MATERIAL<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.2.1.1. GLASS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.2.1.2. PLASTIC<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.2.2. BY PRODUCT<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.2.2.1. EMPTY SYRINGES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.2.2.2. PREFILLED SYRINGES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.2.3. BY USABLITY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.2.3.1. REUSABLE SYRINGES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.2.3.2. DISPOSABLE SYRINGES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;6.3. SELF INJECTION DEVICES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.3.1. NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.1. BY PRODUCT<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.3.1.2. BY TECHNOLOGY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.3. BY USABILITY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.3.2. AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.1. BY PRODUCT<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.1.1. EMPTY AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.1.2. PREFILLED AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.2. BY TECHNOLOGY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.2.1. AUTOMATED AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.2.2. MANUAL AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.3. BY DESIGN<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.3.1. STANDARDIZED AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.3.2. CUSTOMIZED AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.4. BY USABILITY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.4.1. REUSABLE AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.4.2. DISPOSABLE AUTOINJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.3.3. PEN INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.3.1. BY PRODUCT<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.3.2. BY DESIGN<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.3.2.1. STANDARDIZED PEN INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.3.2.2. CUSTOMIZED PEN INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.3.3. BY USABILITY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.3.1. REUSABLE PEN INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6.3.2.3.2. DISPOSABLE PEN INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.3.4. WEARABLE INJECTORS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.3.5. OTHER INJECTABLE DEVICES<\/p>\n<p style=\"text-align: justify;\">7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;7.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 7.2.1. SOLUTIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 7.2.2. RECONSTITUTED\/LYOPHILIZED FORMULATIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 7.2.3. SUSPENSIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 7.2.4. EMULSIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;7.3. NOVEL DRUG DELIVERY FORMULATIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 7.3.1. COLLOIDAL DISPERSIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.1.1. LIPOSOMES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.1.2. NIOSOMES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.1.3. POLYMERIC MIXED MICELLES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.1.4. NANOPARICLES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.1.4.1. NANOSUSPENSIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.1.4.2. NANOEMULSIONS\/MICROEMULSIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.1.4.3. SOLID LIPID NANOPARTICLES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 7.3.2. MICROPARTICLES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.2.1. MICROSPHERES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;7.3.2.2. MICROCAPSULES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 7.3.3. LONG ACTING INJECTION FORMULATIONS<\/p>\n<p style=\"text-align: justify;\">8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;8.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;8.2. AUTOIMMUNE DISEASES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.2.1. RHEUMATOID ARTHRITIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.2.2. MULTIPLE SCLEROSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.2.3. CHRON&rsquo;S DISEASE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.2.4. PSORIASIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.2.5. OTHER AUTOIMMUNE DISEASES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;8.3. HORMONAL DISORDERS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.3.1. DIABETES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.3.2. ANEMIA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.3.3. REPRODUCTIVE HEALTH DISEASE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.3.4. ANTITHROMBOTIC\/THROMBOLYTIC THERAPY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.3.5. OSTEOPOROSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.3.6. GROWTH HORMONE DEFICIENCY (GHD)<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;8.4. ORPHAN DISEASES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;8.5. ONCOLOGY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;8.6. OTHERS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.6.1. PAIN MANAGEMENT<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.6.2. ALERGY TREATMENT<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.6.3. AESTHETIC TREATMENTS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.6.4. HEPATITIS C<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8.6.5. HEMOPHILIA<\/p>\n<p style=\"text-align: justify;\">9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;9.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;9.2. CURATIVE CARE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;9.3. IMMUNIZATIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)<\/p>\n<p style=\"text-align: justify;\">10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;10.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;10.2. SKIN<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;10.3. CIRCULATORY\/MUSKOSKELETAL<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;10.4. ORGANS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;10.5. CENTRAL NERVOUS SYSTEM<\/p>\n<p style=\"text-align: justify;\">11. INJECTABLE DRUG DELIVERY MARKET, BY END USER<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;11.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;11.2. HOSPITALS AND CLINICS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;11.3. HOME HEALTHCARE SETTINGS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;11.4. RESEARCH LABORATORIES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;11.6. OTHER END USERS<\/p>\n<p style=\"text-align: justify;\">12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;12.1. COUNTRYWISE &nbsp;INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12.1.1. NORTH AMERICA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.1.1. U.S.<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.1.2. CANADA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12.1.1.3. MEXICO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12.1.2. EUROPE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.1. GERMANY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.2. FRANCE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.3. U.K.<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.4. ITALY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.5. SPAIN<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.6. RUSSIA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.7. TURKEY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12.1.2.8. BELGIUM<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.9. NETHERLANDS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12.1.2.7. SWITZERLAND<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.2.8. REST OF EUROPE<\/p>\n<p style=\"text-align: justify;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12.1.3. ASIA-PACIFIC (APAC)<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.1. JAPAN<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.2. CHINA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.3. SOUTH KOREA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.4. INDIA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.5. AUSTRALIA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.6. SINGAPORE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.7. THAILAND<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.8. MALAYSIA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.9. INDONESIA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.10. PHILIPPINES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.3.11. REST OF APAC<\/p>\n<p style=\"text-align: justify;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12.1.4. LATIN AMERICA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.4.1. BRAZIL<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.4.2. REST OF LATIN AMERICA<\/p>\n<p style=\"text-align: justify;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12.1.5. MIDDLE EAST AND AFRICA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.5.1. SOUTH AFRICA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12.1.5.2. REST OF MIDDLE EAST AND AFRICA<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES<\/p>\n<p style=\"text-align: justify;\">13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.6. MIDDLE EAST AND AFRICA &nbsp;INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.7. MERGERS &amp; ACQUISITIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.8. NEW PRODUCT DEVELOPMENT &amp; APPROVALS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.9. EXPANSIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.10. REGULATORY CHANGES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS<\/p>\n<p style=\"text-align: justify;\">14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.1. BAXTER INTERNATIONAL, INC.<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.1.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.1.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.1.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.1.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.1.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.2. BECTON, DICKINSON AND COMPANY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.2.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.2.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.2.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.2.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.2.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.3. GERRESHEIMER, AG<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.3.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.3.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.3.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.3.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.3.5. ANALYST VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.4. PFIZER, INC.<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.4.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.4.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.4.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.4.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.4.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.5. SCHOTT AG<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.5.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.5.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.5.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.5.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.5.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.6. ALKERMES PLC<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.6.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.6.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.6.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.6.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.6.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.7. ELI LILLY AND COMPANY<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.7.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.7.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.7.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.7.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.7.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.8. SANDOZ<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.8.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.8.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.8.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.8.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.8.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.9. TERUMO CORPORATION<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.9.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.9.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.9.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.9.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.9.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.10.1. OVERVIEW<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.10.2. SWOT ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.10.3. PRODUCT PORTFOLIO<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.10.4. REVENUE ANALYSIS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 14.10.5. ANALYSTS VIEW<\/p>\n<p style=\"text-align: justify;\">15. APPENDIX<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;15.1. RELATED REPORTS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;15.2. CUSTOMIZABLE OPTIONS<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;15.3. SOURCE SHEET<\/p>\n<p style=\"text-align: justify;\">&nbsp; &nbsp; &nbsp; &nbsp;15.4. BIBLIOGRAPHY<\/p>\n<p style=\"text-align: justify;\">16. ABOUT DATA BRIDGE MARKET RESEARCH<\/p>\n<p style=\"text-align: justify;\"><strong><br \/>About Data Bridge Market Research:<\/strong><\/p>\n<p style=\"text-align: justify;\">Data Bridge is an organization lead by well versed forecasters, analysts and researchers who indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction to cater to your business needs. Data Bridge aims to make your organization well acquainted with profound knowledge of the global and local market statistics.<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"http:\/\/databridgemarketresearch.com\/reports\/global-radiopharmaceuticals-market-trends-forecast-2024\/\">Global Radiopharmaceuticals Market &ndash; Industry Trends and Forecast to 2024<\/a><\/p>\n<p style=\"text-align: justify;\">By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)&ndash; Industry Trends andForecast To 2024<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> Data Bridge Market Research Private Limited<br \/><strong>Contact Person:<\/strong> Varsha Chaudhari<br \/><strong>Email:<\/strong> Sales@databridgemarketresearch.com<br \/><strong>Phone:<\/strong> +1-888-387-2818<br \/><strong>Address:<\/strong>Office Number 317, Amanora Chambers, Magarpatta Road, Hadapsar  <br \/><strong>City:<\/strong> Pune<br \/><strong>State:<\/strong> Maharashtra<br \/><strong>Country:<\/strong> India<br \/><strong>Website:<\/strong> <a href=\"http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/\" target=\"_blank\" rel=\"nofollow\">http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/\" style=\"width:605px; height:400px;\"><\/object><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=global-injectable-drug-delivery-market-will-be-worth-usd-7897-billion-by-2024-new-market-report-by-data-bridge-market-research\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Global Injectable Drug Delivery Market is expected to grow at 11.5% in the forecast period 2017 to 2024&#8221; Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/global-injectable-drug-delivery-market-will-be-worth-usd-7897-billion-by-2024-new-market-report-by-data-bridge-market-research_122121.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-122121","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/122121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=122121"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/122121\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=122121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=122121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=122121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}